Mark D. Booth
2011
In 2011, Mark D. Booth earned a total compensation of $1.7M as Chief Commercial Officer at Orexigen Therapeutics, a 50% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $170,740 |
|---|---|
| Option Awards | $1,248,766 |
| Salary | $234,333 |
| Other | $7,501 |
| Total | $1,661,340 |
Booth received $1.2M in option awards, accounting for 75% of the total pay in 2011.
Booth also received $170.7K in non-equity incentive plan, $234.3K in salary and $7.5K in other compensation.
Rankings
In 2011, Mark D. Booth's compensation ranked 3,877th out of 10,747 executives tracked by ExecPay. In other words, Booth earned more than 63.9% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 3,877 out of 10,747 | 64th |
Division Manufacturing | 1,360 out of 3,960 | 66th |
Major group Chemicals And Allied Products | 272 out of 1,033 | 74th |
Industry group Drugs | 155 out of 781 | 80th |
Industry Pharmaceutical Preparations | 127 out of 571 | 78th |
Source: SEC filing on April 30, 2014.
Booth's colleagues
We found five more compensation records of executives who worked with Mark D. Booth at Orexigen Therapeutics in 2011.
2011
Michael Narachi
Orexigen Therapeutics
Chief Executive Officer
2011
Heather Turner
Orexigen Therapeutics
General Counsel
2011
Preston Klassen
Orexigen Therapeutics
Head of Global NB32 Program and Senior Vice President, Product Development
2011
Joseph Hagan
Orexigen Therapeutics
Chief Business Officer
2011
Graham Cooper
Orexigen Therapeutics